Dolutegravir Lamivudine and Tenofovir Disoproxil Fumarate Tablets

Product Description

The combination of Dolutegravir (DTG), Lamivudine (3TC), and Tenofovir Disoproxil Fumarate (TDF) is a widely used antiretroviral medication for the treatment of HIV-1 infection. This combination is often provided in a fixed-dose tablet, simplifying the treatment regimen for individuals living with HIV. Here are some key points about this combination:

1. Dolutegravir (DTG):

   • DTG is an integrase strand transfer inhibitor (INSTI).
   • It works by inhibiting the integrase enzyme, preventing the integration of viral DNA into the host cell genome, which is essential for the replication of the HIV virus.

2. Lamivudine (3TC):

   • 3TC is a nucleoside reverse transcriptase inhibitor (NRTI).
   • It inhibits the reverse transcriptase enzyme, preventing the replication of the HIV virus.

3. Tenofovir Disoproxil Fumarate (TDF):

   • TDF is also a nucleotide reverse transcriptase inhibitor (NRTI).
   • It inhibits the reverse transcriptase enzyme, disrupting the replication of the HIV virus.

Key points about the combination (Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate tablets):

• Indications: This combination is used for the treatment of HIV-1 infection in adults and pediatric patients.

• Dosage: The typical dosage involves taking one tablet orally once daily. The specific dosage may vary depending on the individuals health condition and the overall HIV treatment plan prescribed by a healthcare professional.

• Adherence: Consistent adherence to the prescribed regimen is crucial for the effectiveness of HIV treatment. Missing doses or not taking the medication as directed can lead to reduced efficacy and the development of drug resistance.

• Side Effects: Potential side effects may include nausea, headache, and fatigue. Its important to report any severe or persistent side effects to a healthcare provider.

• Pregnancy: The use of this combination during pregnancy should be discussed with a healthcare provider, taking into consideration the potential risks and benefits.

• Resistance: Adherence is critical to prevent the development of resistance. If resistance occurs, it may compromise the effectiveness of the treatment.

Individuals prescribed with this combination should follow the guidance of their healthcare provider, undergo regular monitoring, and communicate any concerns or side effects experienced during the treatment. As always, individual circumstances may vary, and healthcare providers can provide personalized information based on the patients medical history and needs

Triple-Drug Antiretroviral Solution

This fixed-dose combination integrates Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate, offering comprehensive suppression of HIV-1 replication. The once-daily regimen simplifies antiretroviral therapy, promoting improved adherence and efficacy. Suitable for adults and adolescents, it is an optimal choice for a diverse range of healthcare providers and markets worldwide.


User-Friendly, Standardized Tablet

Supplied as standard adult-sized, oval film-coated tablets, the medicine is easy to swallow and designed for consistent dosing. The tablets come in robust blister packs or bottles, making them convenient for storage and distribution. The products physical stability ensures reliable potency throughout its 24-month shelf life when stored correctly.